Use of precision medicine in oncology is burgeoning and can provide patients with new treatment options. However, it is not clear how precision medicine is impacting healthcare professionals (HCPs), particularly with regards to their concerns about this new approach. We therefore synthesized the existing literature on HCPs’ attitudes toward cancer precision medicine. We searched four databases for relevant articles. Two reviewers screened eligible articles and extracted data. We assessed the quality of each article using the QualSyst tool. We found 22 articles, representing 4,321 HCPs (63.7% cancer specialists). HCPs held largely positive attitudes toward cancer precision medicine, including their capacity to facilitate treatment decisions and provide prognostic information. However, they also had concerns regarding costs, insurance coverage, limited HCP knowledge about precision medicine, potential misuse, difficulties accessing the tests, and delays in receiving test results. Most HCPs felt that test-related decisions should be shared between families and HCPs. HCPs intended to disclose actionable results but were less inclined to disclose negative/secondary findings. HCPs had a strong preference for genetic counselor involvement when disclosing germline findings. Most HCPs intended to use somatic and germline tests in their future practice but the extent to which pharmacogenomic tests will be used is uncertain. HCPs indicated that additional evidence supporting test utility and increased availability of treatment guidelines could facilitate the use of testing. HCPs held generally positive attitudes toward cancer precision medicine, however there were some key concerns. Addressing concerns early, devising educational support for HCPs and developing guidelines may facilitate the successful implementation of precision medicine trials in the future.

精准医学在肿瘤学中的应用正在蓬勃发展，可以为患者提供新的治疗选择。然而，目前尚不清楚精准医疗对医疗保健专业人员 (HCP) 有何影响，特别是他们对这种新方法的担忧。因此，我们综合了有关 HCP 对癌症精准医疗态度的现有文献。我们在四个数据库中搜索了相关文章。两名审稿人筛选符合条件的文章并提取数据。我们使用 QualSyst 工具评估了每篇文章的质量。我们发现了 22 篇文章，代表 4,321 名 HCP（63.7% 是癌症专家）。医疗保健专业人员对癌症精准医疗持积极态度，包括他们促进治疗决策和提供预后信息的能力。然而，他们也担心费用、保险范围、医护人员对精准医疗的了解有限、潜在的滥用、获得测试的困难以及接收测试结果的延迟。大多数 HCP 认为与测试相关的决定应由家庭和 HCP 共同承担。HCP 打算披露可采取行动的结果，但不太愿意披露负面/次要发现。在披露种系发现时，HCP 强烈倾向于遗传咨询师的参与。大多数 HCP 打算在未来的实践中使用体细胞和种系测试，但药物基因组测试的使用程度尚不确定。HCP 表示，支持检测实用性的更多证据和增加治疗指南的可用性可以促进检测的使用。医疗保健专业人员对癌症精准医疗总体持积极态度，但也存在一些关键担忧。及早解决问题、为 HCP 提供教育支持并制定指南可能有助于未来精准医学试验的成功实施。